Statements (48)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
vaccine
|
| gptkbp:clinicalTrials |
over 30,000
multiple countries Phase 3 |
| gptkbp:contraindication |
fatigue
headache muscle pain nausea fever joint pain |
| gptkbp:developedBy |
gptkb:Novavax
|
| gptkbp:drugInterdiction |
two
|
| gptkbp:emergencyServices |
gptkb:United_States
|
| gptkbp:evaluates |
approximately 90% in clinical trials
|
| gptkbp:firstAppearance |
December 2021
|
| gptkbp:firstHeld |
initial vaccination
|
| https://www.w3.org/2000/01/rdf-schema#label |
Nuvaxovid
|
| gptkbp:marketedAs |
Covovax_in_some_regions
|
| gptkbp:notable_player |
post-marketing surveillance
collaboration with international organizations conditional marketing authorization non-replicating viral vector against variants of concern global distribution efforts ongoing studies for variant effectiveness stable at refrigerated temperatures reduces severe disease and hospitalization affordable pricing for low-income countries |
| gptkbp:patentFamily |
yes
|
| gptkbp:produces |
gptkb:India
gptkb:South_Korea gptkb:United_States |
| gptkbp:providesSupportFor |
gptkb:GAVI_Alliance
gptkb:COVAX_Facility various governments |
| gptkbp:raisesAwarenessAbout |
yes
|
| gptkbp:regulatoryCompliance |
gptkb:Health_Canada
gptkb:European_Medicines_Agency gptkb:UK_Medicines_and_Healthcare_products_Regulatory_Agency |
| gptkbp:reproduction |
available on health authority websites
|
| gptkbp:route |
intramuscular
|
| gptkbp:sequel |
booster vaccination
|
| gptkbp:storage |
2 to 8 degrees Celsius
|
| gptkbp:takesPlaceIn |
part of global vaccination strategy
|
| gptkbp:targets |
gptkb:COVID-19
|
| gptkbp:triggerType |
induces immune response against spike protein
|
| gptkbp:type |
protein subunit vaccine
|
| gptkbp:updates |
regular updates on efficacy and safety
|